Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HM30-tesirine
- Development stage
- Preclinical
- Lead developer
- AgilVax
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HM30-tesirine is an antibody-drug conjugate (ADC) designed to target the xCT subunit (encoded by the SLC7A11 gene) of the system xc- cystine/glutamate antiporter. Developed by AgilVax, the drug consists of the HM30 monoclonal antibody conjugated to tesirine (SG3249), a potent pyrrolobenzodiazepine (PBD) dimer cytotoxin. The xCT transporter is a critical component of the cellular antioxidant defense system and is frequently upregulated in various malignancies, particularly non-small cell lung cancer (NSCLC) harboring NRF2-KEAP1 pathway mutations. By binding to xCT on the tumor cell surface, HM30-tesirine is internalized and releases its tesirine payload, which induces lethal DNA interstrand cross-links. Preclinical studies have demonstrated that HM30-tesirine effectively suppresses tumor growth and improves survival in aggressive, therapy-resistant models of NSCLC.
- Other names
- anti-xCT ADCHM30-PBDHM-30-PBDHM 30-PBD
02
Targets
SLC7A11 (Cystine-Glutamate Antiporter)DNA
Beyond the preview
Go deeper on HM30-tesirine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HM30-tesirine.